Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 4:33 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 47 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Piperacillin/Tazobactam Clear all
Terminated Phase 4 Interventional Results available

BL Infusion Trial:Beta-lactam Continuous Versus Intermittent Infusion and Associated Bacterial Resistance and Therapy Outcomes in Critically Ill Patients With Severe Pneumonia

NCT05102162
View directory record Official record
Conditions
Pneumonia
Interventions
Cefepime, Meropenem, or Piperacillin/Tazobactam
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 100 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced Oct 26, 2026, 4:33 AM EDT
Terminated Phase 2 Interventional Results available

Efficacy of Oral Antibiotic Therapy Compared to Intravenous Antibiotic Therapy for Osteomyelitis

NCT02168816
View directory record Official record
Conditions
Osteomyelitis
Interventions
Intravenous Antibacterial Agent, Oral Antibacterial Agent
Drug
Lead sponsor
Loyola University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 19, 2018 · Synced Oct 26, 2026, 4:33 AM EDT
Terminated Phase 3 Interventional

Pivotal Study in Nosocomial Pneumonia Suspected or Confirmed to be Due to Pseudomonas

NCT03582007
View directory record Official record
Conditions
Pneumonia
Interventions
Murepavadin, One anti-pseudomonal antibiotic
Drug
Lead sponsor
Polyphor Ltd.
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
2
States / cities
Iowa City, Iowa • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 26, 2026, 4:33 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Comparison of Medical and Surgical Treatment of Uncomplicated Acute Appendicitis in Children

NCT02991937
View directory record Official record
Conditions
Appendicitis
Interventions
Piperacillin/Tazobactam, Surgical Treatment
Drug · Procedure
Lead sponsor
NYU Langone Health
Other
Eligibility
6 Years to 17 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 21, 2022 · Synced Oct 26, 2026, 4:33 AM EDT
Completed Phase 3 Interventional Results available

Efficacy/Safety of Meropenem-Vaborbactam Compared to Piperacillin-Tazobactam in Adults With cUTI and AP

NCT02166476
View directory record Official record
Conditions
Urinary Tract Infection Complicated, Acute Pyelonephritis
Interventions
Meropenem-Vaborbactam, Piperacillin-Tazobactam, Levofloxacin, Saline
Drug
Lead sponsor
Melinta Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
8
States / cities
Mobile, Alabama • San Diego, California • Denver, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2018 · Synced Oct 26, 2026, 4:33 AM EDT
Terminated Early Phase 1 Interventional

Patients Response to Early Switch To Oral:Osteomyelitis Study

NCT02099240
View directory record Official record
Conditions
Osteomyelitis
Interventions
oral antibiotics, intravenous antibiotics
Drug · Procedure
Lead sponsor
Julio Ramirez
Other
Eligibility
18 Years to 100 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 6, 2021 · Synced Oct 26, 2026, 4:33 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Antibiotic Safety (SCAMP)

NCT01994993
View directory record Official record
Conditions
Complicated Intra Abdominal Infections
Interventions
ampicillin and metronidazole and gentamicin, ampicillin and gentamicin and clindamycin, gentamicin and Piperacillin- tazobactam, standard of care antibiotics and metronidazole, metronidazole, clindamycin, or piperacillin-tazobactam
Drug
Lead sponsor
Michael Cohen-Wolkowiez
Other
Eligibility
Up to 120 Days
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
45
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Loma Linda, California + 35 more
Source: ClinicalTrials.gov public record
Updated May 30, 2019 · Synced Oct 26, 2026, 4:33 AM EDT
Completed Not applicable Interventional

Standard vs. Biofilm Susceptibility Testing in Cystic Fibrosis (CF)

NCT00153634
View directory record Official record
Conditions
Cystic Fibrosis, Chronic Bronchitis
Interventions
IV amikacin, PO azithromycin, IV ceftazidime, PO ciprofloxacin, IV meropenem, IV piperacillin-tazobactam, IV ticarcillin-clavulanate, IV tobramycin
Drug
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
14 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
8
States / cities
Iowa City, Iowa • St Louis, Missouri • Cincinnati, Ohio + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2008 · Synced Oct 26, 2026, 4:33 AM EDT
Terminated Phase 2 Interventional Results available

Comparative Study of Ceftazidime-Avibactam Versus Standard of Care as Therapy in Febrile Neutropenic Adults With Cancer

NCT02732327
View directory record Official record
Conditions
Neoplasms, Febrile Neutropenia
Interventions
CAZ-AVI, Vancomycin, Linezolid, Cefepime, Meropenem, Piperacillin/tazobactam
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 21, 2017 · Synced Oct 26, 2026, 4:33 AM EDT
Active, not recruiting Phase 2 Interventional

Choosing the Best Antibiotic to Protect Friendly Gut Bacteria During the Course of Stem Cell Transplant

NCT03078010
View directory record Official record
Conditions
Intestinal Microbiome, Febrile Neutropenia
Interventions
Piperacillin-tazobactam, cefepime
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
347 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
2
States / cities
Hackensack, New Jersey • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Oct 26, 2026, 4:33 AM EDT
Recruiting Phase 4 Interventional

A Pragmatic Clinical Trial Comparing the Risk of Acute Kidney Injury During Treatment With Vancomycin and Piperacillin-Tazobactam vs. Vancomycin and Cefepime in Hospitalized Patients

NCT06954129
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
Vancomycin, Piperacillin-tazobactam, Cefepime
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 26, 2026, 4:33 AM EDT
Completed No phase listed Observational

Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care

NCT01431326
View directory record Official record
Conditions
Adenovirus, Anesthesia, Anxiety, Anxiolysis, Autism, Autistic Disorder, Bacterial Meningitis, Bacterial Septicemia, Benzodiazepine, Bipolar Disorder, Bone and Joint Infections, Central Nervous System Infections, Convulsions, Cytomegalovirus Retinitis, Early-onset Schizophrenia Spectrum Disorders, Epilepsy, General Anesthesia, Gynecologic Infections, Herpes Simplex Virus, Infantile Hemangioma, Infection, Inflammation, Inflammatory Conditions, Intra-abdominal Infections, Lower Respiratory Tract Infections, Migraines, Pain, Pneumonia, Schizophrenia, Sedation, Seizures, Skeletal Muscle Spasms, Skin and Skin-structure Infections, Treatment-resistant Schizophrenia, Urinary Tract Infections, Withdrawal, Sepsis, Gram-negative Infection, Bradycardia, Cardiac Arrest, Cardiac Arrhythmia, Staphylococcal Infections, Nosocomial Pneumonia, Neuromuscular Blockade, Methicillin Resistant Staphylococcus Aureus, Endocarditis, Neutropenia, Headache, Fibrinolytic Bleeding, Pulmonary Arterial Hypertension, CMV Retinitis, Hypertension, Chronic Kidney Diseases, Hyperaldosteronism, Hypokalemia, Heart Failure, Hemophilia, Heavy Menstrual Bleeding, Insomnia
Interventions
The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:
Drug
Lead sponsor
Daniel Benjamin
Other
Eligibility
Up to 21 Years
Enrollment
3,520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
43
States / cities
Anchorage, Alaska • Little Rock, Arkansas • La Jolla, California + 37 more
Source: ClinicalTrials.gov public record
Updated Sep 6, 2023 · Synced Oct 26, 2026, 4:33 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

SYN-004 Safety and Tolerability in Allo-HCT Subjects

NCT04692181
View directory record Official record
Conditions
Acute Graft-Versus-Host Reaction Following Bone Marrow Transplant, Prevention of CDI in Adult Patients Being Treated With IV Beta-lactam Antibiotics
Interventions
SYN-004, Ribaxamase or Placebo
Biological
Lead sponsor
Theriva Biologics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Oct 26, 2026, 4:33 AM EDT
Active, not recruiting Phase 2 Interventional

RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD)

NCT04514653
View directory record Official record
Conditions
Neovascular Age-Related Macular Degeneration (nAMD)
Interventions
Ranibizumab, ABBV-RGX-314 Dose 1, ABBV-RGX-314 Dose 2, ABBV-RGX-314 Dose 3, Local Steroid, Topical Steroid, ABBV-RGX-314 Dose 4
Biological · Genetic · Drug
Lead sponsor
AbbVie
Industry
Eligibility
50 Years to 89 Years
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
18
States / cities
Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 26, 2026, 4:33 AM EDT
Completed Phase 3 Interventional

Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count

NCT00003805
View directory record Official record
Conditions
Bone Marrow Suppression, Fever, Sweats, and Hot Flashes, Infection, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
piperacillin sodium, piperacillin-tazobactam, tazobactam sodium, vancomycin
Drug
Lead sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Network
Eligibility
2 Years and older
Enrollment
859 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
2
States / cities
Baltimore, Maryland • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 24, 2012 · Synced Oct 26, 2026, 4:33 AM EDT
Completed Phase 4 Interventional Results available

Optimal Care of Complicated Appendicitis

NCT03159754
View directory record Official record
Conditions
Appendicitis, Perforated Appendicitis, Ruptured Appendicitis, Complicated Appendicitis
Interventions
Early Appendectomy, Interval Appendectomy, Antibiotics
Procedure · Drug
Lead sponsor
University of Michigan
Other
Eligibility
5 Years to 17 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 28, 2023 · Synced Oct 26, 2026, 4:33 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Two Different Antibiotics Versus One Antibiotic for Pediatric Perforated Appendicitis

NCT03289351
View directory record Official record
Conditions
Perforated Appendicitis, Postoperative Infection
Interventions
Piperacillin, Tazobactam Drug Combination
Drug
Lead sponsor
Phoenix Children's Hospital
Other
Eligibility
Up to 18 Years
Enrollment
162 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2023
U.S. locations
2
States / cities
Phoenix, Arizona • Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 12, 2024 · Synced Oct 26, 2026, 4:33 AM EDT
Recruiting Not applicable Interventional

Gram-Negative Bloodstream Infection Oral Antibiotic Therapy Trial

NCT06080698
View directory record Official record
Conditions
Gram-negative Bacteremia
Interventions
Intravenous Antibiotics, Oral Antibiotics
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
1,030 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
11
States / cities
San Francisco, California • Denver, Colorado • Baltimore, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Oct 26, 2026, 4:33 AM EDT
Recruiting No phase listed Observational

Shorter Versus Extended Course of Antibiotic Therapy for Necrotizing Soft Tissue Infections

NCT06002607
View directory record Official record
Conditions
Necrotizing Soft Tissue Infection
Interventions
Antibiotic duration (short course), Antibiotic duration (extended course)
Other
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Oct 26, 2026, 4:33 AM EDT
Withdrawn Phase 2 Interventional

Fecal Transplant +/- Gut Decontamination in Preventing Acute Graft Versus Host Disease in Patients Given Broad-Spectrum Antibiotics

NCT03862079
View directory record Official record
Conditions
Graft-versus-host Disease Prevention
Interventions
Best Practice, Fecal Microbiota Transplantation, Nystatin, Piperacillin-Tazobactam
Other · Procedure · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
16 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 4, 2020 · Synced Oct 26, 2026, 4:33 AM EDT
Recruiting Phase 3 Interventional

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

NCT02735707
View directory record Official record
Conditions
Community-acquired Pneumonia, Influenza, COVID-19
Interventions
Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, P2Y12 inhibitor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Angiotensin Receptor Blockers, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Remdesivir, Nirmatrelvir/ritonavir + remdesivir
Drug · Other · Biological + 1 more
Lead sponsor
UMC Utrecht
Other
Eligibility
18 Years and older
Enrollment
20,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
11
States / cities
Jacksonville, Florida • Augusta, Georgia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2024 · Synced Oct 26, 2026, 4:33 AM EDT
Completed Phase 2 Interventional Results available

Comparative Study To Determine The Efficacy, Safety, And Tolerability Of Ceftolozane-Tazobactam

NCT03485950
View directory record Official record
Conditions
Other Infectious Diseases
Interventions
Cefepime, Ceftolozane, Laboratory Biomarker Analysis, Meropenem, Piperacillin-Tazobactam, Tazobactam
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 15, 2022 · Synced Oct 26, 2026, 4:33 AM EDT
Recruiting Phase 2 Interventional

Cefotetan Therapy for Escherichia Coli Infections

NCT07318584
View directory record Official record
Conditions
E Coli Infection, ESBL Producing E.Coli
Interventions
Cefotetan, Carbapenems, Beta Lactam Antibiotics
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 26, 2026, 4:33 AM EDT
Terminated Phase 4 Interventional Results available

Effects of Therapy With Sulfamylon® 5% Topical Solution Compared to a Historical Control Group

NCT00634166
View directory record Official record
Conditions
Burns
Interventions
Sulfamylon® For 5 % Topical Solution, Topical Antimicrobial/Antifungal Medications
Drug
Lead sponsor
Mylan Inc.
Industry
Eligibility
3 Months and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
9
States / cities
Mobile, Alabama • Redlands, California • Gainesville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2022 · Synced Oct 26, 2026, 4:33 AM EDT